Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agalimmune Receives £1.2 million ($2 million) Milestone Payment

Published: Wednesday, June 04, 2014
Last Updated: Wednesday, June 04, 2014
Bookmark and Share
Agalimmune’s Alphaject technology, an injectable oncology therapy has completed a Phase I trial in melanoma. Data presented at AACR and ASCO.

Agalimmune Ltd announced today that it has received a milestone payment from Loxbridge Research LLP and Animatrix Finance Ltd following successful completion of two Phase I trials of its AlphajectTM technology in late stage cancer patients. The investment will be used to fund Agalimmune’s research into combination therapy with immune checkpoint inhibitors such as the CTLA-4, PD-1, and PD-L1 classes of compounds, as part of its supportive preclinical work packages.

The milestone payment represents continued investment into the Company, and is being made in response to the promising early clinical data from two separate Phase I trials involving twenty patients. The more recent trial, funded by the US National Institutes of Health, and performed at University of Wisconsin in Madison, WI, focused on late-stage melanoma patients. The results were reported in a poster presented at AACR, the American Association for Cancer Research conference, with a second poster presented this past week at ASCO, the American Society for Clinical Oncology conference.

Agalimmune is focused on the development of an anti-tumor injectable technology that harnesses pre-existing immunity present in all humans. Agalimmune’s Alphaject technology includes methods for treating solid tumors in such a way that the immune system actively rejects them, akin to a non-matched graft or transplant. Tumors are directly injected with the Alphaject compound, to which humans naturally have a high antibody titer. Alphaject coats the tumor cells in alpha-Gal, thereby presenting a foreign antigen to the immune system. This is thought to bring about a 'hyper-acute rejection' of the tumor, and breaks the immune tolerance shielding it from attack, allowing the immune system to both begin to destroy the tumor immediately and also over time, to confer a long-lasting protection in the form of enhanced immune surveillance. The effect is analogous to a personalized cancer vaccine, acting continuously to prevent both metastasis and recurrence. A short animation to show the mechanism of action of Alphaject can be viewed here: http://youtu.be/pIiWgQRa66o

Key findings presented in the AACR and ASCO posters were that in two of the nine patients, new melanoma-associated antigen specific T-Cells were found following treatment with Alphaject. Most significantly, also in two of nine patients, new necrosis of non-injected lesions was observed, suggesting effective systemic action of activated specific killer T-Cells, a key marker of likelihood of immune effect on survival. The posters can be viewed here: http://www.agalimmune.com/images/ZulegerCindy_AACR_2014.pdf, and http://www.agalimmune.com/images/ASCO_AlphaGal%20Poster%202014.pdf

Dr Charles Roberts, CEO of Loxbridge, commented: “We are delighted to see the Alphaject program advance. We believe that Alphaject has the potential to become an important addition to the oncologist’s arsenal in treating patients with potentially fatal solid tumors. The technology is perfectly suited to symbiotic activity with immune checkpoint blockade agents, and we are already seeing interest from a number of the developers of these drugs. I anticipate a combination trial in future with checkpoint blockade, and hope to see the synergies proven clinically.”  
 
Mike Westby, CEO of Agalimmune, added “We are encouraged by the results of the Wisconsin trial, in which repeated Alphaject injections were safe and induced promising immune responses in a subset of these advanced patients.  Immune priming is an important component of inducing a protective anti-tumor response. Alphaject is designed to induce a personalized immune priming against the patient’s own tumor; we believe therefore it can become an important component of effective immunotherapeutic combination regimens."



Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
"Sunscreen" Gene May Guard Against Melanoma
USC-led study reveals that melanoma patients with deficient or mutant copies of the gene are less protected from harmful ultraviolet rays.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!